Trials / Completed
CompletedNCT02919696
A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
A Phase 1 Study of Abemaciclib in Native Chinese Patients With Advanced and/or Metastatic Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety of the study drug known as abemaciclib in native Chinese participants with advanced and/or metastatic cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
Timeline
- Start date
- 2017-08-07
- Primary completion
- 2018-11-23
- Completion
- 2019-09-03
- First posted
- 2016-09-29
- Last updated
- 2020-09-25
- Results posted
- 2020-09-25
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02919696. Inclusion in this directory is not an endorsement.